




Searching News Database: Gram-Negative
HSMN NewsFeed - 17 Jun 2021
Irrimax Receives FDA Clearance for Irrisept(R) as an Antimicrobial Wound Lavage for US Market
Irrimax Receives FDA Clearance for Irrisept(R) as an Antimicrobial Wound Lavage for US Market
HSMN NewsFeed - 25 May 2021
BD Launches Industry First Ready-to-Use Iodine-Based Surgical Irrigation System
BD Launches Industry First Ready-to-Use Iodine-Based Surgical Irrigation System
HSMN NewsFeed - 2 Jan 2020
Aridis Pharmaceuticals Appoints Michael A. Nazak as Chief Financial Officer
Aridis Pharmaceuticals Appoints Michael A. Nazak as Chief Financial Officer
HSMN NewsFeed - 25 Oct 2019
Microbion Corporation Announces Generic Name for Lead Antimicrobial Compound: Pravibismane
Microbion Corporation Announces Generic Name for Lead Antimicrobial Compound: Pravibismane
HSMN NewsFeed - 19 Jul 2019
Aridis Pharmaceuticals Receives Orphan Drug Designation From the European Medicines Agency for AR-501
Aridis Pharmaceuticals Receives Orphan Drug Designation From the European Medicines Agency for AR-501
HSMN NewsFeed - 10 Jun 2019
Aridis Pharmaceuticals Appoints Dr. Susan Windham-Bannister to Board of Directors
Aridis Pharmaceuticals Appoints Dr. Susan Windham-Bannister to Board of Directors
HSMN NewsFeed - 18 Mar 2019
Allergan Announces FDA Approval of AVYCAZ(R) (ceftazidime and avibactam) for Pediatric Patients
Allergan Announces FDA Approval of AVYCAZ(R) (ceftazidime and avibactam) for Pediatric Patients
HSMN NewsFeed - 15 Jan 2018
BD and Check-Points Receive CE Mark for Next-generation Resistant Bacteria Screening Test
BD and Check-Points Receive CE Mark for Next-generation Resistant Bacteria Screening Test
HSMN NewsFeed - 8 Mar 2017
Spero Therapeutics Secures $51.7 Million in Oversubscribed Series C Financing
Spero Therapeutics Secures $51.7 Million in Oversubscribed Series C Financing
HSMN NewsFeed - 18 Aug 2016
FDA Grants Soligenix Orphan Drug Designation for Dusquetide for Treatment of Macrophage Activation Syndrome
FDA Grants Soligenix Orphan Drug Designation for Dusquetide for Treatment of Macrophage Activation Syndrome
HSMN NewsFeed - 31 May 2016
Allergan Receives FDA Approval of TEFLARO(R) (ceftaroline fosamil) for Pediatric Patients
Allergan Receives FDA Approval of TEFLARO(R) (ceftaroline fosamil) for Pediatric Patients
HSMN NewsFeed - 17 Mar 2016
Biota Pharmaceuticals Announces Sale of Antibiotic Assets to Spero Therapeutics
Biota Pharmaceuticals Announces Sale of Antibiotic Assets to Spero Therapeutics
HSMN NewsFeed - 16 Feb 2016
FDA Accepts Supplemental New Drug Application (sNDA) for TEFLARO(R) (ceftaroline fosamil)
FDA Accepts Supplemental New Drug Application (sNDA) for TEFLARO(R) (ceftaroline fosamil)
HSMN NewsFeed - 5 Mar 2015
Tetraphase Pharmaceuticals Appoints Maria Stahl as Senior Vice President and General Counsel
Tetraphase Pharmaceuticals Appoints Maria Stahl as Senior Vice President and General Counsel
HSMN NewsFeed - 5 Dec 2014
Basilea Announces Launch of Antibiotic Zevtera(R) (ceftobiprole medocaril) in Germany
Basilea Announces Launch of Antibiotic Zevtera(R) (ceftobiprole medocaril) in Germany
HSMN NewsFeed - 30 Sep 2014
Catheter Connections Fails Additional Disinfection Test on Second Common Bacteria, Announces Ivera Medical
Catheter Connections Fails Additional Disinfection Test on Second Common Bacteria, Announces Ivera Medical
HSMN NewsFeed - 24 Sep 2014
Catheter Connections Fails Disinfection Test on Second Common Bacteria, Announces Ivera Medical
Catheter Connections Fails Disinfection Test on Second Common Bacteria, Announces Ivera Medical
HSMN NewsFeed - 16 Sep 2014
Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners
Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners
HSMN NewsFeed - 18 Jun 2014
Lakewood-Amedex Raises $5.5 Million In Series C Preferred Stock Financing
Lakewood-Amedex Raises $5.5 Million In Series C Preferred Stock Financing
HSMN NewsFeed - 5 Jun 2014
ORBACTIV(TM) (Oritavancin) Phase 3 Trial Results Published in New England Journal of Medicine
ORBACTIV(TM) (Oritavancin) Phase 3 Trial Results Published in New England Journal of Medicine
HSMN NewsFeed - 20 May 2014
Spero Therapeutics Appoints Thomas Parr, Ph.D. as Chief Scientific Officer
Spero Therapeutics Appoints Thomas Parr, Ph.D. as Chief Scientific Officer
HSMN NewsFeed - 19 May 2014
Nektar Appoints Ivan Gergel, M.D. as Senior Vice President, Drug Development & Chief Medical Officer
Nektar Appoints Ivan Gergel, M.D. as Senior Vice President, Drug Development & Chief Medical Officer
HSMN NewsFeed - 16 Sep 2013
FDA Grants Soligenix Orphan Drug Designation for SGX94 for Treatment of Acute Radiation Syndrome
FDA Grants Soligenix Orphan Drug Designation for SGX94 for Treatment of Acute Radiation Syndrome
HSMN NewsFeed - 25 Jun 2013
BioFire Receives FDA Clearance for the FilmArray(R) Blood Culture Identification Panel
BioFire Receives FDA Clearance for the FilmArray(R) Blood Culture Identification Panel
HSMN NewsFeed - 28 Feb 2013
FDA Grants QIDP and Fast Track Designations for Cubist’s Late-Stage Antibiotic Candidates
FDA Grants QIDP and Fast Track Designations for Cubist’s Late-Stage Antibiotic Candidates
HSMN NewsFeed - 4 Apr 2011
Anacor Pharmaceuticals Appoints William J. Rieflin to Its Board of Directors
Anacor Pharmaceuticals Appoints William J. Rieflin to Its Board of Directors
HSMN NewsFeed - 17 Jan 2011
AdvanDx Receives FDA 510(k) Clearance for GNR Traffic Light(TM) PNA FISH(R)
AdvanDx Receives FDA 510(k) Clearance for GNR Traffic Light(TM) PNA FISH(R)
HSMN NewsFeed - 1 Dec 2010
Cubist Pharmaceuticals Receives FDA Approval for 2-Minute IV Injection of CUBICIN
Cubist Pharmaceuticals Receives FDA Approval for 2-Minute IV Injection of CUBICIN
HSMN NewsFeed - 5 Oct 2010
Anacor Pharmaceuticals Appoints Geoffrey M. Parker as Chief Financial Officer
Anacor Pharmaceuticals Appoints Geoffrey M. Parker as Chief Financial Officer
HSMN NewsFeed - 21 Jun 2010
APP Pharmaceuticals Announces Approval and Launch of First Generic Aztreonam for Injection, USP
APP Pharmaceuticals Announces Approval and Launch of First Generic Aztreonam for Injection, USP
HSMN NewsFeed - 24 Mar 2010
FDA Approves XIFAXAN(R) 550 MG Tablets for Reduction in Risk of Overt Hepatic Encephalopathy (HE) Recurrence
FDA Approves XIFAXAN(R) 550 MG Tablets for Reduction in Risk of Overt Hepatic Encephalopathy (HE) Recurrence
HSMN NewsFeed - 27 Nov 2009
Theravance Receives Complete Response Letter on the Telavancin NDA for the Treatment of Nosocomial Pneumonia
Theravance Receives Complete Response Letter on the Telavancin NDA for the Treatment of Nosocomial Pneumonia
HSMN NewsFeed - 16 Sep 2009
Rib-X Pharmaceuticals, Inc. Appoints Tony Zook of MedImmune to Board of Directors
Rib-X Pharmaceuticals, Inc. Appoints Tony Zook of MedImmune to Board of Directors
HSMN NewsFeed - 30 Jan 2009
AdvanDx Receives FDA 510(k) Clearance for E. coli/P. aeruginosa PNA FISH(R)
AdvanDx Receives FDA 510(k) Clearance for E. coli/P. aeruginosa PNA FISH(R)
HSMN NewsFeed - 2 Dec 2008
Cubist Names Santosh J. Vetticaden as SVP, Clinical Development and Chief Medical Officer
Cubist Names Santosh J. Vetticaden as SVP, Clinical Development and Chief Medical Officer
HSMN NewsFeed - 26 Nov 2008
FDA Issues Complete Response Letter for Ceftobiprole for Treatment of Complicated Skin Infections
FDA Issues Complete Response Letter for Ceftobiprole for Treatment of Complicated Skin Infections
HSMN NewsFeed - 3 Sep 2008
Rib-X Pharmaceuticals, Inc. Appoints Dr. Joseph Amprey of MedImmune Ventures to Board of Directors
Rib-X Pharmaceuticals, Inc. Appoints Dr. Joseph Amprey of MedImmune Ventures to Board of Directors
HSMN NewsFeed - 16 Jul 2008
Sagent Pharmaceuticals Launches Ceftriaxone, USP, and Cefuroxime for Injection, USP
Sagent Pharmaceuticals Launches Ceftriaxone, USP, and Cefuroxime for Injection, USP
HSMN NewsFeed - 2 Jul 2008
Cubist Pharmaceuticals to Promote in the U.S. AstraZeneca's Broad Spectrum Antibiotic, MERREM I.V.
Cubist Pharmaceuticals to Promote in the U.S. AstraZeneca's Broad Spectrum Antibiotic, MERREM I.V.
HSMN NewsFeed - 21 Apr 2008
APP Pharmaceuticals Receives FDA Approval for Colistimethate For Injection, USP
APP Pharmaceuticals Receives FDA Approval for Colistimethate For Injection, USP
HSMN NewsFeed - 18 Mar 2008
FDA issues Approvable Letter for ceftobiprole, a new anti-MRSA broad-spectrum antibiotic
FDA issues Approvable Letter for ceftobiprole, a new anti-MRSA broad-spectrum antibiotic
HSMN NewsFeed - 4 Mar 2008
Cardinal Health Agrees to Acquire ChloraPrep(R) Manufacturer for $490 Million
Cardinal Health Agrees to Acquire ChloraPrep(R) Manufacturer for $490 Million
HSMN NewsFeed - 5 Dec 2007
Theravance Announces Positive Topline Results In Phase 3 Telavancin Hospital-Acquired Pneumonia Program
Theravance Announces Positive Topline Results In Phase 3 Telavancin Hospital-Acquired Pneumonia Program
HSMN NewsFeed - 16 Oct 2007
Cubist Pharmaceuticals Announces Exclusive Option to Acquire Illumigen Biosciences
Cubist Pharmaceuticals Announces Exclusive Option to Acquire Illumigen Biosciences
HSMN NewsFeed - 8 Oct 2007
Dade Behring Receives FDA Clearance for Rapid-Result Gram Positive Microbiology Tests
Dade Behring Receives FDA Clearance for Rapid-Result Gram Positive Microbiology Tests
HSMN NewsFeed - 18 Sep 2007
New Data Show Doripenem as Effective as Commonly Used Therapies in Treating Hospital-Acquired Pneumonias
New Data Show Doripenem as Effective as Commonly Used Therapies in Treating Hospital-Acquired Pneumonias
HSMN NewsFeed - 6 Sep 2007
Cubist Pharmaceuticals' CUBICIN Approved for Additional Indications in the EU
Cubist Pharmaceuticals' CUBICIN Approved for Additional Indications in the EU
HSMN NewsFeed - 28 Aug 2007
Cubist Pharmaceuticals Creates COO Position, Adds Scientific Advisory Board
Cubist Pharmaceuticals Creates COO Position, Adds Scientific Advisory Board
HSMN NewsFeed - 18 May 2007
New Drug Application Submitted For Novel Investigational Antibiotic Ceftobiprole
New Drug Application Submitted For Novel Investigational Antibiotic Ceftobiprole
HSMN NewsFeed - 10 Jan 2007
Basilea Announces Positive Top-Line Results On Second Pivotal Phase III Ceftobiprole Trial
Basilea Announces Positive Top-Line Results On Second Pivotal Phase III Ceftobiprole Trial
HSMN NewsFeed - 14 Dec 2006
Cerexa to Be Acquired by Forest Laboratories for $480 Million Plus Potential $100 Million Milestone Payment
Cerexa to Be Acquired by Forest Laboratories for $480 Million Plus Potential $100 Million Milestone Payment
Additional items found! 48

Members Archive contains
48 additional stories matching:
Gram-Negative
(Password required)
Gram-Negative
(Password required)